Wearable robots learn to sell themselves

Lifeward teams with Verita Neuro to expand ReWalk distribution, highlighting how partnerships and service models are shaping commercial growth in wearable robotics

13 Jan 2026

Wearable robotics has quietly crossed an important line. What was once confined to research labs and small pilot programs is now a competitive commercial market, where speed and execution matter as much as clever engineering.

That shift is clear in Lifeward’s latest move. The company has teamed up with Verita Neuro to expand distribution of its ReWalk Personal Robotic Exoskeleton in Mexico, Thailand, and the United Arab Emirates. Announced in a December press release, the deal reflects a broader change taking place across the mobility robotics industry.

Innovation alone is no longer enough.

ReWalk is designed to help people with mobility impairments stand and walk, offering what many users describe as a life changing experience. But wearable robotics is not a simple device sale. Clinics need training. Patients need careful fitting. Systems require ongoing technical support to work safely and consistently. Without that infrastructure, even advanced technology can struggle to gain traction.

This is where regional partners come in. Companies like Verita Neuro already operate within local healthcare systems and understand how to support clinicians day to day. That knowledge can shorten the path from product launch to real world use.

Lifeward CEO Larry Jasinski described Verita Neuro as a leading healthcare company and said the partnership marks an important step in expanding access to ReWalk technology across the three regions. For Lifeward, the agreement offers a faster and more capital efficient way to enter promising international markets without building full local teams from scratch.

For Verita Neuro, the appeal is different. Adding a recognized wearable robotics platform could attract rehabilitation providers looking to differentiate their services and offer advanced mobility options to patients.

The bigger takeaway extends beyond this one deal. As wearable robotics matures, competition is increasingly shaped by execution. Companies that can train clinicians, support patients over time, and maintain reliable service are better positioned to build trust and drive adoption. Strong technology still matters, but it is no longer the sole deciding factor.

Partnerships also bring risk. If training or support falls short, early experiences can slow momentum in new markets. The margin for error is small.

Still, the direction is clear. Wearable robotics is entering a new phase, one defined by partnerships, speed, and real world delivery. For patients waiting on better mobility solutions, that shift could make a meaningful difference.